ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2948

Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study

Sinem Nihal Esatoglu1, Ibrahim Hatemi2, Yesim Ozguler3, Gulen Hatemi3, Hafize Uzun4, Aykut Ferhat Celik5 and Hasan Yazici3, 1Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome, biomarkers and inflammatory bowel disease (IBD)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The fecal calprotectin (FC) is widely used as a non-invasive method for identifying patients with active Crohn’s disease (CD) and ulcerative colitis. Gastrointestinal involvement of Behçet’s syndrome (GIBS) shows clinical and endoscopic similarities to CD. A previous study in a small number of Behçet’s syndrome (BS) patients with mainly mucocutaneous lesions showed serum calprotectin levels did not differ between active and inactive patients (1). Another study suggested FC may help to diagnose GIBS patients (2). We are not aware of studies addressing whether FC helps to distinguish active GIBS patients from those in remission. Therefore, we aimed to determine whether FC helped to predict active disease in GIBS patients.

Methods:  We collected fecal specimens and serum from 23 GIBS (11 M, 12 F and mean age 44±9 yrs) patients before colonoscopy. The reasons for colonoscopy were assessing active disease in patients presenting with abdominal pain (with or without diarrhea) (n=9) or confirmation of a remission in asymptomatic patients (n=14). Seven of these patients had active GI involvement and the remaining 16 were inactive, based on colonoscopic findings. We also included 22 active and 25 inactive CD patients as controls. We used 150 µg/g as the cut-off for a positive FC level. We also looked at the correlations between FC and serum calprotectin and CRP levels, Crohn’s disease activity index (CDAI) and disease activity index for intestinal Behçet’s disease (DAIBD) scores.

Results: FC was >150 µg/g in all of the 7 GIBS patients with ulcers compared to 4/16 of GIBS patients without ulcers (OR: 42, 95%CI: 2 to 888). The median FC of active GIBS patients (n=7) was significantly higher than among inactive GIBS patients (n=16) (325 µg/g (IQR: 187-1800) vs 44 µg/g (IQR: 30-154); p=0.002). The mean serum calprotectin level was also higher among the active GIBS patients, however the difference was not significant (173.0 ± 273.7 µg/g vs 102.0 ± 135.4, p=0.13). There was a very low correlation between FC and serum calprotectin levels (r=0.08, p=0.72), a moderate correlation between FC and serum CRP levels (r=0.66, p=0.76), a moderate correlation between FC and CDAI scores (r=0.55, p=0.006) and very low correlation between FC and DAIBD scores (r=0.01, p=0.96). Among CD patients, 16/25 of the active patients and 3/22 of the patients in remission had FC level >150 µg/g (OR: 2.6, 95%CI: 3 to 49). Among the 4 GIBS patients who had high FC levels despite being in remission for gastrointestinal involvement, 1 had active mucocutaneous lesions, 1 had concomitant macrophage activation syndrome, and 1 had polycythemia vera with trisomy 8. None of the patients were receiving NSAIDs that could increase FC levels.

Conclusion: With further work FC may turn out to be a useful non-invasive tool for ruling out active GI lesions in asymptomatic GIBS patients. A high FC level demands caution for the presence of active ulcers especially in symptomatic patients while whether the presence of other BS manifestations can cause false positive results remains to be studied.


Disclosure: S. N. Esatoglu, None; I. Hatemi, None; Y. Ozguler, None; G. Hatemi, None; H. Uzun, None; A. F. Celik, None; H. Yazici, None.

To cite this abstract in AMA style:

Esatoglu SN, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik AF, Yazici H. Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/fecal-calprotectin-level-is-useful-in-identifying-active-disease-in-behcets-syndrome-patients-with-gastrointestinal-involvement-a-controlled-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fecal-calprotectin-level-is-useful-in-identifying-active-disease-in-behcets-syndrome-patients-with-gastrointestinal-involvement-a-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology